news

FDA grants orphan drug status to Cellect’s ApoGraft

25
SHARES

The FDA has granted orphan drug designation for ApoGraft for the prevention of acute and chronic graft versus host disease… 

FDA

The U.S. Food and Drug Administration (FDA) has granted orphan drug designation for ApoGraft for the prevention of acute and chronic graft versus host disease(GvHD) in transplant patients to Cellect Biotechnology Ltd. 

 

ACCESS your FREE COPY

 


This report addresses the key factors shaping pharmaceutical formulation, including regulation, QC and analysis.

Access the full report now to discover the techniques, tools and innovations that are transforming pharmaceutical formulation, and learn how to position your organisation for long-term success.

What you’ll discover:

  • Key trends shaping the pharmaceutical formulation sector
  • Innovations leading progress in pharmaceutical formulation and how senior professionals can harness their benefits
  • Considerations and best practices when utilising QbD during formulation of oral solid dosage forms
  • And more!

Don’t miss your chance to access this exclusive report ! Access now – it’s free

GvHD is a transplant associated disease representing an outcome of two immune systems crashing into each other. In many transplantations from donors, and especially in Bone Marrow Transplantations (BMT), the transplanted immune mature cells attack the host and create severe morbidity and in many cases even death.

This disease happens as a result of current practices being unable to separate the GvHD causing cells from the much-needed stem cells.  ApoGraf was designed to eliminate immune responses in any transplantation of foreign cells and tissues.

ApoGraft technology can be utilised and has already helped thousands of development and research centres globally engaged in adult stem cells based therapeutics by providing them with a simplified and cost efficient enriched stem cells for use as a raw material for a wide range of stem cells based therapeutics R&D. 

Before ApoGraft, such procedures were extremely complex, inefficient and required substantial resources in both cost, time and infrastructure requirements. ApoGraft can now be used to significantly advance the use of stem cells across multiple therapeutics indications as well as research and biobanking purposes.

Leave a Reply

Your email address will not be published. Required fields are marked *

Share via
Share via